Thr464
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr464  -  RAMP (human)

Site Information
DLPLPsNtPTFSIKt   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4717290

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 3 , 4 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 , 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
bone cancer ( 2 ) , breast cancer ( 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
CDK1 (human) ( 2 )
Kinases, in vitro:
CDK1 (human) ( 2 ) , CDK2 (human) ( 2 )
Treatments:
D4476 ( 2 ) , DMAT ( 2 ) , GSK-3_inhibitor_IX ( 2 ) , PD98059 ( 2 ) , PP242 ( 2 ) , RO-3306 ( 2 ) , SB203580 ( 2 ) , seliciclib ( 2 ) , serum ( 2 ) , TGF-beta ( 2 ) , U0126 ( 2 )

Downstream Regulation
Effects of modification on RAMP:
molecular association, regulation ( 1 , 2 ) , protein stabilization ( 1 , 2 ) , ubiquitination ( 2 )
Effects of modification on biological processes:
cell cycle regulation ( 1 , 2 ) , cell differentiation, induced ( 2 )
Induce interaction with:
14-3-3 epsilon (human) ( 1 ) , 14-3-3 gamma (human) ( 1 )
Inhibit interaction with:
FBXO11 (human) ( 2 )

References 

1

Dar A, et al. (2014) 14-3-3 proteins play a role in the cell cycle by shielding cdt2 from ubiquitin-mediated degradation. Mol Cell Biol 34, 4049-61
25154416   Curated Info

2

Rossi M, et al. (2013) Regulation of the CRL4(Cdt2) Ubiquitin Ligase and Cell-Cycle Exit by the SCF(Fbxo11) Ubiquitin Ligase. Mol Cell 49, 1159-66
23478441   Curated Info

3

Guo A (2011) CST Curation Set: 12020; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

4

Guo A (2011) CST Curation Set: 12022; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info